News & Updates

Put Life Back in Your Patients’ Hands: Winning the fight Against Peripheral Neuropathy in Diabetic Patients

Dear Doctor,  

In celebration of World Diabetes Day, P&G Health Philippines, in partnership with the Philippine Association of Family Physicians (PAFP), Philippine Society of Endocrinology, Diabetes and Metabolism (PSEDM), and the Cavite Medical Society (CMS) recently held the “Put Life Back in Your Patients’ Hands: Winning the Fight against Neuropathy in Diabetes” physical-digital event for healthcare professionals, we made sure you don’t miss the updates and innovations in nerve care that were discussed. 

Catch the highlights of the “phygital” event here.  

Diabetes Mellitus DMT2 GLP1-RA Dulaglutide

Zvolution - Making Healthcare More Accessible

Staying true to its long history of committed partnership with healthcare professionals on Continuing Medical Education (CME) and product innovation, ZP Therapeutics made a grand return to face-to-face CME events in celebration of ZP Therapeutics’ illustrious 100-year history as a leading healthcare industry partner. The ZPT Exposition of Experts in Improving Patient Outcomes 2022, themed “Zvolution -Making Healthcare More Accessible”, was held at the Conrad Hotel in Pasay City last 23–24 September 2022 and featured a panel of top-notch speakers whose talks covered a broad range of topics from digital health solutions to Gastroenterology, bone health, immunity as well as critical care in diabetes, and Cardiology. 

Dapagliflozin DELIVERs across full HF spectrum regardless of LVEF

The selective, oral sodium–glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin reduces the risk of cardiovascular (CV) death or worsening heart failure (HF) in patients with HF and mildly reduced or preserved ejection fraction (HFmrEF or HFpEF) in the phase III DELIVER* trial, touted as the largest and most inclusive thus far in this patient group.

Product Highlight - Lantus

Insulin Glargine 100 units/mL vial

Product Highlight - Apidra Solostar

Insulin Glulisine 100 units/mL pre-filled pen

Product Highlight - SOLIQUA

Insulin glargine + Lixisenatide 100 u/mL + 50 mcg/mL solution for injection (3 mL pre-filled pen); 100 u/mL + 33 mcg/mL solution for injection (3 mL pre-filled pen)

Product Highlight - TOUJEO

Insulin Glargine 300 units/mL pre-filled pen

Diabetes Mellitus, Updates on Diabetes Mellitus

Early and consistent: Breakthrough results in HFpEF similar to HFrEF

HFpEF represents a significant unmet need in CV medicine due to its prevalence, poor prognosis, and the absence of clinically proven therapeutic options. The EMPEROR-Preserved trial demonstrated the continuous clinical benefits in cardiorenal outcomes of empagliflozin in adults with HFpEF, which were consistent with the observations in adults with HFmrEF/ HFpEF in the EMPEROR-reduced trial. The combined results of the EMPEROR trials establish empagliflozin’s efficacy in heart failure regardless of ejection fraction – and if approved, empagliflozin would become the first and only clinically proven therapy to improve outcomes for the full spectrum of the disease. Therefore, empagliflozin offers a new hope for people living with heart failure.